Press "Enter" to skip to content

Aytu BioPharma publishes in vitro data demonstrating UV-A light increases mitochondrial anti-viral signaling protein within cells

ENGLEWOOD, CO / May 17, 2021 / Aytu BioPharma, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, reported financial results for the fiscal third quarter ended March 31, 2021 and provided recent business highlights. The Company also disclosed that in May 2021, Aytu announced the publication of…

This content is viewable by members only. Visit MY ACCOUNT on the top menu to log in or to register for a 30 day free trial or purchase a subscription for UV Reporter 1 Year Single Membership or UV Reporter 1 Year Group Membership - $189 for first member and $25 for each additional member.